7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,633.19

+345.59

+0.45%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

Swiss - Delayed Quote CHF

Idorsia Ltd (IDIA.SW)

4.4700 -0.1120 (-2.44%)

At close: October 30 at 5:30:30 PM GMT+1

Loading Chart for IDIA.SW

Chart Range Bar

Interval:

In partnership with ChartIQ

Idorsia reports accelerating QUVIVIQ growth, advances key value drivers, and reaffirms full-year financial guidance

Idorsia reports accelerating QUVIVIQ growth, advances key value drivers, and reaffirms full-year financial guidance

Idorsia and SPV investors partner to unlock the blockbuster potential of TRYVIO/JERAYGO with a targeted launch in specialists

Idorsia and SPV investors partner to unlock the blockbuster potential of TRYVIO/JERAYGO with a targeted launch in specialists

Idorsia initiates pivotal Phase 3 study for lucerastat in Fabry disease and enters co-development and commercialization agreement with Nxera

Idorsia initiates pivotal Phase 3 study for lucerastat in Fabry disease and enters co-development and commercialization agreement with Nxera

Idorsia seeks US label update for QUVIVIQ daytime functioning benefits – first patients enrolled in Dari-Dream

Idorsia seeks US label update for QUVIVIQ daytime functioning benefits – first patients enrolled in Dari-Dream

A new scientific avenue for daridorexant: Idorsia to advance development in autism spectrum disorder

A new scientific avenue for daridorexant: Idorsia to advance development in autism spectrum disorder

Idorsia (SWX:IDIA) Dropped, What Is Behind The Latest Attention?

Idorsia (SWX:IDIA) Dropped, What Is Behind The Latest Attention?

Idorsia (SWX:IDIA) Stock Could Be Fully Priced On Current Sales

Idorsia (SWX:IDIA) Stock Could Be Fully Priced On Current Sales

Idorsia acknowledges the DEA proposal to reclassify dual orexin receptor antagonists to the lowest schedule – Schedule V

Idorsia acknowledges the DEA proposal to reclassify dual orexin receptor antagonists to the lowest schedule – Schedule V

QUVIVIQ sales increased 62% year-on-year as Idorsia advances key drivers of future growth

QUVIVIQ sales increased 62% year-on-year as Idorsia advances key drivers of future growth

Invitation to Idorsia's HY 2026 Financial Reporting webcast and conference call

Invitation to Idorsia's HY 2026 Financial Reporting webcast and conference call

Idorsia appoints Roland Wandeler as Chief Executive Officer

Idorsia appoints Roland Wandeler as Chief Executive Officer

Mobilize your Website

View Site in Mobile | Classic

Share by: